PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) will release its financial
results for the quarter ended March 31, 2015, after the close of market
on Wednesday, May 6, 2015. The announcement will be followed by a
conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management
will discuss Anacor's financial results and recent developments. The
call may be accessed by dialing (877) 291-1367 (domestic) and (914)
495-8534 (international) five minutes prior to the start of the call.
The call will also be webcast live and may be accessed on the Events and
Presentations page, under Investors, on Anacor's website at www.anacor.com
where it will be available for three months following the call.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing
and commercializing novel small-molecule therapeutics derived from its
boron chemistry platform. Anacor's first approved drug, KERYDIN®
(tavaborole) topical solution, 5%, is an oxaborole antifungal approved
by the U.S. Food and Drug Administration in July 2014 for the topical
treatment of onychomycosis of the toenails. In July 2014, Anacor entered
into an exclusive agreement with Sandoz Inc., a Novartis company,
pursuant to which PharmaDerm, the branded dermatology division of
Sandoz, distributes and commercializes KERYDIN in the United States. In
September 2014, PharmaDerm launched KERYDIN in the United States.
Anacor's lead product development candidate is AN2728, an
investigational non-steroidal topical PDE-4 inhibitor for the potential
treatment of mild-to-moderate atopic dermatitis and psoriasis. Beyond
KERYDIN and AN2728, Anacor has discovered three investigational
compounds that it has out-licensed for further development. The first
compound is licensed to Eli Lilly and Company for the potential
treatment of an animal health indication. The second compound, AN5568,
also referred to as SCYX-7158, is licensed to Drugs for Neglected
Diseases initiative for the potential treatment of human African
trypanosomiasis. The third compound is licensed to GlaxoSmithKline LLC
for development in tuberculosis. Anacor also has a pipeline of other
internally discovered topical and systemic boron-based compounds in
early stages of research and development. These include AN3365, an
investigational Gram-negative antibiotic, and certain other wholly-owned
investigational product candidates. For more information, visit http://www.anacor.com.
